Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How BP plc (ADR) (BP) Measures up as a GARP Investment

LONDON — A popular way to dig out reasonably priced stocks with robust growth potential is through the “Growth at a Reasonable Price”, or GARP, strategy. This theory uses the price-to-earnings to growth (PEG) ratio to show how a share’s price weighs up in relation to its near-term growth prospects — a reading below one is generally considered decent value for money.

BP plc (ADR) (NYSE:BP)

Today I am looking at BP plc (ADR) (NYSE:BP) to see how it measures up.

What are BP’s earnings expected to do?

2013 2014
EPS Growth 36% 12%
P/E Ratio 8.4 7.5
PEG Ratio 0.2 0.6

Source: Digital Look

BP plc (ADR) (NYSE:BP) is expected to recover strongly from last year’s 55% earnings per share (EPS) dip in the medium term, according to broker estimates, with chunky earnings expansion predicted for both this year and next.

This projected rebound leaves the company’s PEG rating for 2013 and 2014 firmly trenched in bargain basement territory. And its price-to-earnings (P/E) ratio for these years also illustrates fantastic value for money — a readout below 10 is generally considered a canny price pick.

Does BP provide decent value against its rivals?

FTSE 100 Oil & Gas Producers
Prospective P/E Ratio 15 22.6
Prospective PEG Ratio 4.4 1.2

Source: Digital Look

BP plc (ADR) (NYSE:BP) easily outperforms both the FTSE 100 and its oil and gas peers in terms of both forward PEG and P/E ratios, both of which fail the “value” test on these measures.

I strongly believe that substantial increases in groupwide output in coming years is set to drive BP’s earnings skywards.

Energy output set to surge
BP’s shell price has declined from multi-month highs recently, as fears over the condition of the global economy, and subsequent concerns over what this means for energy prices, has dented investor appetite for the stock.

As well, the lengthy court battle over the 2010 Gulf of Mexico oil spill continues to drag on, extending uncertainty over what the final payout could be — the firm has attached a total cumulative charge of $42.2 billion, although the final bill could still exceed this. As well, news that European regulators raided BP’s London premises last month over possible oil price manipulation prompted more bad press for the oil giant.

Still, I believe that these concerns are overshadowing the company’s strong growth profile which rising production should create. After bringing online five mammoth projects in 2012, the company is preparing to get a further four up and running this year and another six next year.

Disposals accounting for 120 thousand barrels per day are set to offset modest underlying growth this year. But falling divestments from next year, allied with rising capex — expenditure of between $24 billion-$25 billion currently is expected to rise to $24 billion-$27 billion from 2014 — should help to push output higher.

Drill for riches with the Fool
As I have explained, BP plc (ADR) (NYSE:BP) comes attached with great growth potential, but there are also other great natural resources opportunities out there waiting to be realized. However, drilling for oil and minerals mining is often a ‘hit and miss’ business where the timing, and indeed quantities, of potential payloads are extremely unpredictable.

The article How BP Measures up as a GARP Investment originally appeared on

Fool contributor Royston Wild has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!